vs
Digimarc CORP（DMRC）与STRATA Skin Sciences, Inc.（SSKN）财务数据对比。点击上方公司名可切换其他公司
STRATA Skin Sciences, Inc.的季度营收约是Digimarc CORP的1.0倍（$9.3M vs $8.9M），STRATA Skin Sciences, Inc.净利率更高（0.6% vs -47.2%，领先47.9%），Digimarc CORP同比增速更快（2.9% vs -3.0%），Digimarc CORP自由现金流更多（$895.0K vs $-551.0K），过去两年STRATA Skin Sciences, Inc.的营收复合增速更高（17.3% vs -5.3%）
迪吉马克公司是一家企业软件与服务提供商，其主打产品包含带数字标识符的软件，主要用于解决防伪问题、验证产品真伪、提升回收准确性以及实现供应链可追溯，产品可广泛应用于服装、快消品、美妆健康、汽车等多个行业领域。
STRATA Skin Sciences是一家美国医疗器械企业，专注于设计、开发并商业化推出非侵入式检测工具，供皮肤科医生在进行黑色素瘤皮肤检查时获取更多辅助诊断信息。
DMRC vs SSKN — 直观对比
营收规模更大
SSKN
是对方的1.0倍
$8.9M
营收增速更快
DMRC
高出5.9%
-3.0%
净利率更高
SSKN
高出47.9%
-47.2%
自由现金流更多
DMRC
多$1.4M
$-551.0K
两年增速更快
SSKN
近两年复合增速
-5.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $8.9M | $9.3M |
| 净利润 | $-4.2M | $58.0K |
| 毛利率 | 63.5% | 61.8% |
| 营业利润率 | -48.2% | 5.3% |
| 净利率 | -47.2% | 0.6% |
| 营收同比 | 2.9% | -3.0% |
| 净利润同比 | 51.4% | 101.3% |
| 每股收益（稀释后） | $-0.18 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DMRCSSKN
| Q4 25 | $8.9M | $9.3M | ||
| Q3 25 | $7.6M | $6.9M | ||
| Q2 25 | $8.0M | $7.7M | ||
| Q1 25 | $9.4M | $6.8M | ||
| Q4 24 | $8.7M | $9.6M | ||
| Q3 24 | $9.4M | $8.8M | ||
| Q2 24 | $10.4M | $8.4M | ||
| Q1 24 | $9.9M | $6.8M |
净利润DMRCSSKN
| Q4 25 | $-4.2M | $58.0K | ||
| Q3 25 | $-8.2M | $-1.6M | ||
| Q2 25 | $-8.2M | $-2.6M | ||
| Q1 25 | $-11.7M | $-2.1M | ||
| Q4 24 | $-8.6M | $-4.6M | ||
| Q3 24 | $-10.8M | $-2.1M | ||
| Q2 24 | $-9.3M | $-91.0K | ||
| Q1 24 | $-10.3M | $-3.4M |
毛利率DMRCSSKN
| Q4 25 | 63.5% | 61.8% | ||
| Q3 25 | 58.3% | 60.4% | ||
| Q2 25 | 58.8% | 56.2% | ||
| Q1 25 | 65.0% | 53.5% | ||
| Q4 24 | 60.8% | 61.4% | ||
| Q3 24 | 62.4% | 60.1% | ||
| Q2 24 | 66.1% | 59.0% | ||
| Q1 24 | 62.5% | 45.6% |
营业利润率DMRCSSKN
| Q4 25 | -48.2% | 5.3% | ||
| Q3 25 | -109.7% | -16.9% | ||
| Q2 25 | -105.2% | -30.1% | ||
| Q1 25 | -128.9% | -25.0% | ||
| Q4 24 | -105.1% | -44.7% | ||
| Q3 24 | -120.4% | -18.2% | ||
| Q2 24 | -96.2% | -5.7% | ||
| Q1 24 | -109.2% | -42.7% |
净利率DMRCSSKN
| Q4 25 | -47.2% | 0.6% | ||
| Q3 25 | -106.9% | -23.4% | ||
| Q2 25 | -102.6% | -33.6% | ||
| Q1 25 | -125.2% | -31.2% | ||
| Q4 24 | -99.9% | -47.6% | ||
| Q3 24 | -113.9% | -23.6% | ||
| Q2 24 | -89.3% | -1.1% | ||
| Q1 24 | -104.0% | -49.8% |
每股收益（稀释后）DMRCSSKN
| Q4 25 | $-0.18 | $0.14 | ||
| Q3 25 | $-0.38 | $-0.36 | ||
| Q2 25 | $-0.38 | $-0.62 | ||
| Q1 25 | $-0.55 | $-0.51 | ||
| Q4 24 | $-0.40 | $-2.01 | ||
| Q3 24 | $-0.50 | $-0.51 | ||
| Q2 24 | $-0.43 | $-0.03 | ||
| Q1 24 | $-0.50 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.9M | $7.9M |
| 总债务越低越好 | — | $15.3M |
| 股东权益账面价值 | $40.2M | $2.9M |
| 总资产 | $53.0M | $30.5M |
| 负债/权益比越低杠杆越低 | — | 5.28× |
8季度趋势，按日历期对齐
现金及短期投资DMRCSSKN
| Q4 25 | $12.9M | $7.9M | ||
| Q3 25 | $12.6M | $7.1M | ||
| Q2 25 | $16.1M | $6.0M | ||
| Q1 25 | $21.6M | $6.5M | ||
| Q4 24 | $28.7M | $7.3M | ||
| Q3 24 | $33.7M | $7.1M | ||
| Q2 24 | $41.5M | $5.5M | ||
| Q1 24 | $48.9M | $5.2M |
总债务DMRCSSKN
| Q4 25 | — | $15.3M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | — | $15.0M | ||
| Q1 24 | — | $15.0M |
股东权益DMRCSSKN
| Q4 25 | $40.2M | $2.9M | ||
| Q3 25 | $41.4M | $1.3M | ||
| Q2 25 | $46.5M | $532.0K | ||
| Q1 25 | $50.0M | $3.0M | ||
| Q4 24 | $61.4M | $5.0M | ||
| Q3 24 | $70.2M | $9.4M | ||
| Q2 24 | $77.2M | $9.5M | ||
| Q1 24 | $84.5M | $9.4M |
总资产DMRCSSKN
| Q4 25 | $53.0M | $30.5M | ||
| Q3 25 | $55.4M | $30.7M | ||
| Q2 25 | $60.7M | $29.5M | ||
| Q1 25 | $66.5M | $33.0M | ||
| Q4 24 | $75.8M | $34.9M | ||
| Q3 24 | $85.0M | $39.4M | ||
| Q2 24 | $93.4M | $38.8M | ||
| Q1 24 | $99.7M | $39.2M |
负债/权益比DMRCSSKN
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | 11.65× | ||
| Q2 25 | — | 28.20× | ||
| Q1 25 | — | 5.04× | ||
| Q4 24 | — | 3.02× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | 1.59× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $991.0K | $-239.0K |
| 自由现金流经营现金流 - 资本支出 | $895.0K | $-551.0K |
| 自由现金流率自由现金流/营收 | 10.0% | -5.9% |
| 资本支出强度资本支出/营收 | 1.1% | 3.4% |
| 现金转化率经营现金流/净利润 | — | -4.12× |
| 过去12个月自由现金流最近4个季度 | $-12.3M | $-4.4M |
8季度趋势，按日历期对齐
经营现金流DMRCSSKN
| Q4 25 | $991.0K | $-239.0K | ||
| Q3 25 | $-2.6M | $-64.0K | ||
| Q2 25 | $-4.7M | $-1.9M | ||
| Q1 25 | $-5.5M | $-550.0K | ||
| Q4 24 | $-4.2M | $703.0K | ||
| Q3 24 | $-7.1M | $-302.0K | ||
| Q2 24 | $-6.8M | $591.0K | ||
| Q1 24 | $-8.4M | $-804.0K |
自由现金流DMRCSSKN
| Q4 25 | $895.0K | $-551.0K | ||
| Q3 25 | $-2.8M | $-1.1M | ||
| Q2 25 | $-4.9M | $-2.0M | ||
| Q1 25 | $-5.5M | $-749.0K | ||
| Q4 24 | $-4.2M | $199.0K | ||
| Q3 24 | $-7.2M | $-364.0K | ||
| Q2 24 | $-6.9M | $246.0K | ||
| Q1 24 | $-8.5M | $-1.5M |
自由现金流率DMRCSSKN
| Q4 25 | 10.0% | -5.9% | ||
| Q3 25 | -36.9% | -15.6% | ||
| Q2 25 | -61.0% | -26.1% | ||
| Q1 25 | -59.1% | -11.0% | ||
| Q4 24 | -49.1% | 2.1% | ||
| Q3 24 | -75.7% | -4.1% | ||
| Q2 24 | -66.1% | 2.9% | ||
| Q1 24 | -85.8% | -22.6% |
资本支出强度DMRCSSKN
| Q4 25 | 1.1% | 3.4% | ||
| Q3 25 | 2.9% | 14.7% | ||
| Q2 25 | 2.5% | 0.8% | ||
| Q1 25 | 0.6% | 2.9% | ||
| Q4 24 | 0.2% | 5.3% | ||
| Q3 24 | 0.7% | 0.7% | ||
| Q2 24 | 0.3% | 4.1% | ||
| Q1 24 | 1.1% | 10.7% |
现金转化率DMRCSSKN
| Q4 25 | — | -4.12× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DMRC
| Subscription | $5.3M | 60% |
| The Government | $3.6M | 41% |
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
